Wassim W. Labaki

Wassim W. Labaki

Auto-generated profile, based on publicly available information

Wassim W. Labaki

University of Michigan, Ann Arbor, United States

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2021 in Annual Review of Medicine
Verified
Journal Article
Closed access
MFMichael C. Ferrera
Michael C. Ferrera
WLWassim W. Labaki
Wassim W. Labaki
MHMeiLan K. Han
MeiLan K. Han
Chronic obstructive pulmonary disease (COPD) is a common respiratory disorder with significant morbidity and mortality. Despite its prevalence, COPD is underdiagnosed, and many patients do not receive a diagnosis until the disease is clinically advanced. Recent basic science and clinical research have focused on the early physiologic and pathobiologic changes in COPD with the hopes of improving diagnosis, providing targets for disease-modifying therapy, and identifying patients most likely to benefit from early intervention. Available treatments for COPD have grown substantially in the past 20 years with the introduction of new oral and inhaled medications as well as novel surgical and bronchoscopic procedures. This article summarizes some of the recent advances in our understanding of disease pathogenesis and treatment paradigms.

1 December 2017 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
WLWassim W. Labaki
Wassim W. Labaki
CMCarlos H. Martinez
Carlos H. Martinez
FMFernando J. Martinez
Fernando J. Martinez
CGCraig J. Galbán
Craig J. Galbán
BRBrian D. Ross
Brian D. Ross
MHMeiLan K. Han
MeiLan K. Han
Chronic obstructive pulmonary disease (COPD) exhibits significant heterogeneity in clinical presentation and rate of disease progression, owing at least in part to differing underlying morphologic abnormalities. Symptom assessment and spirometry have traditionally been used to determine disease severity and guide management. However, chest computed tomography (CT) is a widely available and increasingly used imaging modality that can provide additional insight into structural and pathophysiologic pulmonary parameters. While chest CT is not currently recommended as part of the routine evaluation for COPD beyond aiding with advanced therapy decision making in severe disease, the expanding use of CT now demands that clinicians understand how to treat relevant information that becomes available. Emphysema, airway disease, air trapping and pulmonary vascular abnormalities have all been associated with a number of important outcomes, including respiratory symptoms, COPD exacerbations and mortality. CT can also provide information on important comorbidities such as coronary artery disease and osteoporosis that have been recognized as essential components of COPD care. While visual assessment of these parameters is already currently routine in chest CT interpretation, quantification methods are becoming more reliable and increasingly accessible to the everyday clinician. In this article, we review the most readily available CT assessment methods and their clinical implications as well as highlight the value of assessing non-pulmonary structures (coronary arteries and vertebral bone). Chest CT clearly has the potential to become a powerful tool in the quest to personalize medicine, but its value will ultimately depend on our ability to extract clinically important information that changes management.

1 November 2017 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
HLHans J. Lee
Hans J. Lee
WLWassim Labaki
Wassim Labaki
DYDiana H. Yu
Diana H. Yu
BSBenjamin Salwen
Benjamin Salwen
CGChristopher Gilbert
Christopher Gilbert
LYLonny Yarmus
Lonny Yarmus
Background: Airway stenting has become an integral part of the therapeutic endoscopic management of obstructive benign and malignant central airway diseases. Despite increased use of airway stents and frequent stent-associated complications, no clear guidelines for surveillance and maintenance exist. This study aim is to elucidate predictive factors associated with development of stent complications, as well as an optimal surveillance period for follow-up bronchoscopy for early detection and possible prevention of stent-associated complications. Methods: Retrospective cohort study of all patients who underwent airway stent placements at our institution from April 2010 to December 2013 for benign and malignant airway diseases. Metallic, silicone (straight, Y stent, T-tube) and hybrid stents were included in the study. Stent complications were analyzed at the time of follow-up bronchoscopy performed four to six weeks after initial stent placement or earlier if patients became symptomatic. Results: The study included 134 patients of which 147 stents were placed. Follow-up bronchoscopy was performed in 94 patients. Symptomatic status at the time of follow-up bronchoscopy was not associated with stent complications [odds ratio (OR) =1.88; 95% CI: 0.79–4.45; P=0.15]. Patient age, sex, indication for stent placement, and stent location, were not associated with development of complications (all P>0.05). Compared to all other stents, hybrid stents were more likely to migrate (OR =6.60; 95% CI: 2.16–20.2; P=0.001) or obstruct by secretions (OR =2.53; 95% CI: 1.10–5.84; P=0.03). There were no complications associated with surveillance bronchoscopy. Conclusions: Surveillance bronchoscopy within 4 to 6 weeks of stent placement may be useful for early detection of complications and their subsequent management, regardless of symptomatic status and indication for stent placement. Prospective multicenter studies are needed to compare optimal surveillance methods and the impact on patient mortality, morbidity and healthcare costs.

1 May 2020 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
Panagis GaliatsatosPanagis Galiatsatos
Panagis Galiatsatos
HWHan Woo
Han Woo
LPLaura M Paulin
Laura M Paulin
AKAmy Kind
Amy Kind
NPNirupama Putcha
Nirupama Putcha
NHNadia N Hansel
Nadia N Hansel
Rationale: Individual socioeconomic status has been shown to influence the outcomes of patients with chronic obstructive pulmonary disease (COPD). However, contextual factors may also play a role. The objective of this study is to evaluate the association between neighborhood socioeconomic disadvantage measured by the area deprivation index (ADI) and COPD-related outcomes. Methods: Residential addresses of SubPopulations and InteRmediate Outcome Measures in COPD Study (SPIROMICS) subjects with COPD (FEV1/FVC < 0.70) at baseline were geocoded and linked to their respective ADI national ranking score at the census block group level. The associations between the ADI and COPD-related outcomes were evaluated by examining the contrast between participants living in the most-disadvantaged (top quintile) to the least-disadvantaged (bottom quintile) neighborhood. Regression models included adjustment for individual-level demographics, socioeconomic variables (personal income, education), exposures (smoking status, packs per year, occupational exposures), clinical characteristics (FEV1% predicted, body mass index) and neighborhood rural status. Results: A total of 1800 participants were included in the analysis. Participants residing in the most-disadvantaged neighborhoods had 56% higher rate of COPD exacerbation (P< 0.001), 98% higher rate of severe COPD exacerbation (P=0.001), a 1.6 point higher CAT score (P< 0.001), 3.1 points higher SGRQ (P< 0.001), and 24.6 meters less six-minute walk distance (P=0.008) compared with participants who resided in the least disadvantaged neighborhoods. Conclusion: Participants with COPD who reside in more-disadvantaged neighborhoods had worse COPD outcomes compared to those residing in less-disadvantaged neighborhoods. Neighborhood effects were independent of individual-level socioeconomic factors, suggesting that contextual factors could be used to inform intervention strategies targeting high-risk persons with COPD.

15 August 2023 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
WLWassim W. Labaki
Wassim W. Labaki
TGTian Gu
Tian Gu
SMSusan Murray
Susan Murray
JCJeffrey L. Curtis
Jeffrey L. Curtis
JWJ. Michael Wells
J. Michael Wells
MHMeiLan K. Han
MeiLan K. Han
Rationale: Cigarette smoking contributes to the risk of death through different mechanisms. Objectives: To determine how causes of and clinical features associated with death vary in tobacco cigarette users by lung function impairment. Methods: We stratified current and former tobacco cigarette users enrolled in Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene) into normal spirometry, PRISm (Preserved Ratio Impaired Spirometry), Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1–2 COPD, and GOLD 3–4 COPD. Deaths were identified via longitudinal follow-up and Social Security Death Index search. Causes of death were adjudicated after a review of death certificates, medical records, and next-of-kin interviews. We tested associations between baseline clinical variables and all-cause mortality using multivariable Cox proportional hazards models. Measurements and Main Results: Over a 10.1-year median follow-up, 2,200 deaths occurred among 10,132 participants (age 59.5 ± 9.0 yr; 46.6% women). Death from cardiovascular disease was most frequent in PRISm (31% of deaths). Lung cancer deaths were most frequent in GOLD 1–2 (18% of deaths vs. 9–11% in other groups). Respiratory deaths outpaced competing causes of death in GOLD 3–4, particularly when BODE index ≥7. St. George’s Respiratory Questionnaire score ≥25 was associated with higher mortality in all groups: Hazard ratio (HR), 1.48 (1.20–1.84) normal spirometry; HR, 1.40 (1.05–1.87) PRISm; HR, 1.80 (1.49–2.17) GOLD 1–2; HR, 1.65 (1.26–2.17) GOLD 3–4. History of respiratory exacerbations was associated with higher mortality in GOLD 1–2 and GOLD 3–4, quantitative emphysema in GOLD 1–2, and airway wall thickness in PRISm and GOLD 3–4. Conclusions: Leading causes of death vary by lung function impairment in tobacco cigarette users. Worse respiratory-related quality of life is associated with all-cause mortality regardless of lung function.

2 January 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
WZWilliam Z. Zhang
William Z. Zhang
MRMichelle C. Rice
Michelle C. Rice
KHKatherine L. Hoffman
Katherine L. Hoffman
COClara Oromendia
Clara Oromendia
IBIgor Barjaktarevic
Igor Barjaktarevic
MCMary E. Choi
Mary E. Choi
BACKGROUND: Mitochondrial dysfunction, a proposed mechanism of chronic obstructive pulmonary disease (COPD) pathogenesis, is associated with the leakage of mitochondrial DNA (mtDNA), which may be detected extracellularly in various bodily fluids. Despite evidence for the increased prevalence of chronic kidney disease in COPD subjects and for mitochondrial dysfunction in the kidneys of murine COPD models, whether urine mtDNA (u-mtDNA) associates with measures of disease severity in COPD is unknown. METHODS: Cell-free u-mtDNA, defined as copy number of mitochondrially encoded NADH dehydrogenase-1 ( MTND1 ) gene, was measured by quantitative PCR and normalized to urine creatinine in cell-free urine samples from participants in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) cohort. Urine albumin/creatinine ratios (UACR) were measured in the same samples. Associations between u-mtDNA, UACR, and clinical disease parameters — including FEV 1 % predicted, clinical measures of exercise tolerance, respiratory symptom burden, and chest CT measures of lung structure — were examined. RESULTS: U-mtDNA and UACR levels were measured in never smokers ( n = 63), smokers without airflow obstruction ( n = 107), participants with mild/moderate COPD ( n = 139), and participants with severe COPD ( n = 166). U-mtDNA was associated with increased respiratory symptom burden, especially among smokers without COPD. Significant sex differences in u-mtDNA levels were observed, with females having higher u-mtDNA levels across all study subgroups. U-mtDNA associated with worse spirometry and CT emphysema in males only and with worse respiratory symptoms in females only. Similar associations were not found with UACR. CONCLUSION: U-mtDNA levels may help to identify distinct clinical phenotypes and underlying pathobiological differences in males versus females with COPD. TRIAL REGISTRATION: This study has been registered at ClinicalTrials.gov ( NCT01969344). FUNDING: US NIH, National Heart, Lung and Blood Institute, supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune, Bayer, Bellerophon Therapeutics, Boehringer-Ingelheim Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Forest Research Institute Inc., GlaxoSmithKline, Grifols Therapeutics Inc., Ikaria Inc., Novartis Pharmaceuticals Corporation, Nycomed GmbH, ProterixBio, Regeneron Pharmaceuticals Inc., Sanofi, Sunovion, Takeda Pharmaceutical Company, and Theravance Biopharma and Mylan.